A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

BACKGROUND Actions of angiotensin II may contribute to the progression of heart failure despite treatment with currently recommended drugs. We therefore evaluated the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard therapy for heart failure. METHODS A total of 5010 patients with heart failure of New York Heart… CONTINUE READING